Starpharma Holdings Limited · ASX:SPL
Starpharma — OTCQX Life Sciences virtual Conference 2015
32 slides from Starpharma's conference presentation, Oct 1, 2015
Slide 1: OTCQX Life Sciences Presentation
For personal use only OTCQX Life Sciences Presentation Melbourne, Australia; 1 October 2015: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast
Slide 2: For personal use only
cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with pot
Slide 3: Corporate Overview
Dr. Jackie Fairley CEO For personal use only STARPHARMA HOLDINGS LIMITED ASX:SPL; OTCQX:SPHRY Corporate Overview September/October 2015
Slide 4: Forward Looking Statements
For personal use only This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targe
Slide 5: One of Australia's most innovative technology companies
One of Australia’s most innovative technology companies • ASX 300 company (ASX:SPL) and US (OTCQX:SPHRY). For personal use only • A platform technology with multiple product opportunities across the pharmaceutical, life science and agrochemical industries. • De-risked business model: • Portfolio of
Slide 6: One of Australia's most innovative biotechnology companies
One of Australia’s most innovative biotechnology companies Starpharma’s portfolio is a mix of internal programs and external commercial partnerships For personal use only Starpharma’s Dendrimer Platform >80 granted patents VivaGel® Portfolio DEP™ Drug Delivery Agrochemicals Bacterial DEP™ Partner Pr
Slide 7: Starpharma's Pharmaceutical Development Portfolio
Starpharma’s Pharmaceutical Development Portfolio For personal use only Res PC PhI PhII PhIII Reg. Mkt BV Symptomatic VivaGel® BV Relief Antimicrobial BV Prevention of VivaGel® BV / Antiviral Recurrence (SPL7013) VivaGel® Condom DEP™ docetaxel Drug Delivery (various cancers) DEP™ oxaliplatin Drug De
Slide 8: EU Marketing Approval granted for VivaGel BV
EU Marketing Approval granted for VivaGel® BV For personal use only • VivaGel® BV gains EU approval for the treatment and rapid relief of BV • Allows for marketing in 28 EU countries & EFTA countries (population >260m women) • EU Approval will be used as the basis for obtaining marketing approvals f
Slide 9: DEP delivery license with AstraZeneca
Starpharma’s DEP™ delivery license with AstraZeneca (LON:AZN) For personal use only • AZ licensed DEP™ drug delivery platform in the development and commercialisation of a novel, proprietary AZ oncology compound • SPL eligible to receive development, launch and sales milestones for the first AZ DEP™
Slide 10: DEP Drug Delivery
For personal use only DEP™ Drug Delivery
Slide 11: DEP docetaxel: Multiple benefits
Starpharma’s DEP™ docetaxel: Multiple benefits For personal use only • Docetaxel (Taxotere®) is a blockbuster chemotherapeutic DEP™ docetaxel vs. Taxotere® • Docetaxel sales: US$3.1B(2012) 1. Elimination of major dose-limiting • Docetaxel is used in major cancer types including breast, side effect (
Slide 12: DEP docetaxel preclinical findings
DEP™ docetaxel preclinical findings: Multiple advantages - Better efficacy and less toxicity For personal use only T1/2 and Targeting Safety Efficacy Patents filed will offer coverage to 2032 10
Slide 13: DEP docetaxel: Phase 1 Clinical Trial
DEP™ docetaxel: Phase 1 Clinical Trial Encouraging initial clinical data For personal use only • Underway at 4 Australian sites* ; Open label study - allowing progressive release of results • Estimated sample: 25-30 cancer patients (various solid tumours) Current Status • DEP™ docetaxel administered
Slide 14: DEP docetaxel Pharmacokinetics in humans
DEP™ docetaxel Pharmacokinetics (PK) in humans cf. Taxotere®^ Enhanced PK in humans For personal use only 1. Extended duration of exposure with DEP™ docetaxel • DEP™ docetaxel plasma half-life substantially longer (~8 x) than Taxotere® (~150x longer in the initial, rapid phases of plasma clearance)
Slide 15: DEP docetaxel compared with BIND's docetaxel
DEP™ docetaxel compared with BIND’s docetaxel Compelling product benefits for DEP™ For personal use only Aspect BIND^ DEP™ docetaxel Starpharma Benefit complex, self assembled SPL dendrimer manufacture readily Manufacture particles; potential for Standard chemistry scalable and validated through ext
Slide 16: Additional DEP candidates
Additional DEP™ candidates For personal use only • SPL’s dendrimer enhanced product (DEP™) nanoparticle technology broad applicability, especially in oncology allows for new patent filings creating proprietary products • Proof of DEP™ concept for docetaxel, doxorubicin, oxaliplatin, methotrexate
Slide 17: Targeted DEP Conjugates (TDCs)
Targeted DEP™ Conjugates (TDCs) A new approach to drug conjugate design For personal use only More than 20 ADC drug licensing deals in the past 5 years 50% of the top 10 products are The top 3 oncology antibodies with products are 2013 sales in antibodies with excess of $US38B combined sales of US$2
Slide 18: VivaGel Portfolio
THE WORLD’S FIRST ANTI-VIRAL CONDOM For personal use only VivaGel® Portfolio
Slide 19: VivaGel Condom - World's first antiviral condom
VivaGel® Condom – World’s first antiviral condom Lifestyles® DUAL PROTECT™ - Available in Australian retail outlets THE For personal use only WORLD’S Extensive consumer research of the VivaGel® condom^: FIRST ANTI- • Confirms strong interest and purchase intent (~90%) VIRAL CONDOM • Strong consumer
Slide 20: VivaGel condom: A compelling and differentiated product
VivaGel® condom: A compelling and differentiated product For personal use only • Condom coated with SPL’s patented antiviral lubricant (VivaGel®) • VivaGel® shown in laboratory studies to inactivate up to 99.9% HIV, HPV & Herpes • Licensed to Ansell and Okamoto (SPL receives royalties on sales) • Re
Slide 21: Bacterial Vaginosis and VivaGel BV: Two product opportunities
Bacterial Vaginosis and VivaGel® BV: Two product opportunities Bacterial Vaginosis: For personal use only • the most common vaginal infection worldwide “It was like gone almost overnight” “I would definitely use it again.” • ~29% women infected in US; up to 51% in some groups “The next day I n
Slide 22: Bacterial Vaginosis and VivaGel BV: Two product opportunities
Bacterial Vaginosis and VivaGel® BV: Two product opportunities For personal use only Drivers of Value Significant Competitive Development and Market Size Advantages Commercial Progress • Unmet need Prevention of • No Approved • Phase 3 Trials Underway (SPA) BV Recurrence • Products >US$1B • Late sta
Slide 23: VivaGel BV Treatment & Symptomatic Relief of BV
VivaGel® BV Treatment & Symptomatic Relief of BV For personal use only • VivaGel® BV gains EU approval for the treatment and rapid relief of BV • Allows for marketing in 28 EU countries & EFTA countries (population >260m women) • EU Approval will be used as the basis for obtaining marketing approval
Slide 24: VivaGel BV: Treatment & Symptomatic Relief of BV
VivaGel® BV : Treatment & Symptomatic Relief of BV Odour Resolution and time to resolution For personal use only 80% ** ** 70% 8.00 60% 7.00 * Time to Resolution (Days) % resolution 50% 6.00 40% Placebo 5.00 86% VivaGel® Placebo 30% 4.00 VivaGel® 20% 3.00 *p<0.05 10% 2.00 ** p<0.001 0% 1.00 SPL7013-
Slide 25: BV Prevention of Recurrence Phase 3 Program
BV Prevention of Recurrence Phase 3 Program For personal use only Two double-blind, multi-centre, randomised trials ~600 p per trial SPA granted by ~100 sites across USA, EU, FDA Asia, Mexico PERIODIC STUDY VISITS “Enriched” R-BV population: Nugent Score 4-10 Primary Endpoint: Recurrence of BV at or
Slide 26: Agrochemicals
For personal use only Agrochemicals
Slide 27: The Opportunity for Starpharma's Priostar Dendrimers in Agrochemicals
The Opportunity for Starpharma’s Priostar® Dendrimers in Agrochemicals For personal use only The Challenge for Priostar® benefits for innovative Agrochemical Companies crop protection formulations • The cost and risk of registering new Better in the can: Better in the field: agrochemical actives to
Slide 28: Starpharma's Priostar Agrochemical Programs
Starpharma’s Priostar® Agrochemical Programs Partnered Priostar® Programs Internal Priostar® Programs For personal use only • Commercial agreements with many of the • SPL is also developing a small number of complete leading global agrochemical companies formulations of selected generic actives with
Slide 29: Priostar Dendrimer Glyphosate Formulation - Field Trial Data
Priostar® Dendrimer Glyphosate Formulation – Field Trial Data For personal use only More effective in hard-to-kill weeds than comparable marketed formulation • Dendrimer product more effective in a number of 100 hard-to-kill weeds than comparable marketed 90 Dendrimer Glyphosate glyphosate product P
Slide 30: Starpharma Holdings - Key Financials
Starpharma Holdings – Key Financials (A$) For personal use only Strong financial position Key Financial Data FY 2015 FY 2014 (Financial Year to 30 June) AUD $M AUD $M Total revenue and income 1.7 1.3 R&D Tax Incentive 3.5 4.2 Net loss after tax (19.0) (14.6) Cash outflow from operations (13.6) (9.8)
Slide 31: Expected Short-Medium Term News Flow
Expected Short-Medium Term News Flow For personal use only VivaGel® Portfolio: • Regulatory approvals for BV Symptomatic Relief product • Commercialisation agreements for BV Symptomatic Relief product • Progress VivaGel® Phase 3 BV Prevention of Recurrence trials • Launches of VivaGel® condom, furth
Slide 32: For Further Information
For Further Information For personal use only Dr Jackie Fairley, CEO +613 8532 2704 Investor.relations@starpharma.com Twitter: @Starpharma_ASX VivaGel® Drug Delivery Agrochemicals 30
Starpharma Holdings — OTCQX Life Sciences virtual Conference 2015 on 6ix